Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02678000 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function
A Phase 2 study of Chronic Kidney Disease (CKD), sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 12
- Study locations
NCT02678000: Completed Phase 2 study of Chronic Kidney Disease (CKD), sponsored by Novartis Pharmaceuticals.
NCT02678000 is a Phase 2 study of Chronic Kidney Disease (CKD) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 84 participants, below the 1,410-participant average among 14 other Chronic Kidney Disease (CKD) trials with a reported enrollment target (94% lower). The trial reports 12 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02678000, a Phase 2 study of Chronic Kidney Disease (CKD), has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 12
- Study locations
Study Summary
This was a randomized, double-blind, parallel group, placebo-controlled study, in two sequential parts that evaluated the renal safety, tolerability and pharmacokinetics of LHW090 in patients with moderately impaired renal function.
Primary Outcome
Any sign or symptom that occurs during the study treatment plus the 30 days post treatment. For LHW090, incidence of AEs by primary organ class presented
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LHW090
Study Locations (12)
Other
- Novartis Investigative Site - Berlin
- Novartis Investigative Site - Elsterwerda
- Novartis Investigative Site - Erlangen
- Novartis Investigative Site - Hamburg
- Novartis Investigative Site - Mannheim
Florida
- Novartis Investigative Site - Miami Lakes
- Novartis Investigative Site - Orlando
Minnesota
- Novartis Investigative Site - Minneapolis
- Novartis Investigative Site - Saint Paul
California
- Novartis Investigative Site - Anaheim
Colorado
- Novartis Investigative Site - Lakewood
Louisiana
- Novartis Investigative Site - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2017-03-10 |
| Est. Completion | 2018-10-11 |
| Phase | Phase 2 |
What the finished NCT02678000 record still lists
NCT02678000 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 1,410-participant average among 14 other Chronic Kidney Disease (CKD) trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Chronic Kidney Disease (CKD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02678000 lists 12 locations in 6 states (Other, Florida, Minnesota).
Frequently Asked Questions
What is clinical trial NCT02678000 about?
NCT02678000 is a clinical study titled "Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function". This was a randomized, double-blind, parallel group, placebo-controlled study, in two sequential parts that evaluated the renal safety, tolerability and pharmacokinetics of LHW090 in patients with moderately impaired renal function.
What is the current status of trial NCT02678000?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2017-03-10. Estimated completion is 2018-10-11.
What conditions does trial NCT02678000 study?
This clinical trial studies the following conditions: Chronic Kidney Disease (CKD).
What interventions are being tested in trial NCT02678000?
The interventions under investigation include: Placebo (DRUG), LHW090 (DRUG).
Who is sponsoring clinical trial NCT02678000?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02678000 being conducted?
This trial has 12 study locations across California, Colorado, Florida, Louisiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease (CKD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02678000's enrollment target sits among peer trials
84 10th of 14 higher than 5 of 14 other Chronic Kidney Disease (CKD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Disease (CKD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
RECRUITING
-
A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)
RECRUITING · Phase 1
-
Exercise and Monitoring With Post-Hospitalization Muscle Atrophy to Sustain Intrinsic Capacity and Strength
RECRUITING · NA
-
Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
RECRUITING
-
Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease
RECRUITING
-
An Intervention to Reduce Sedentary Behavior for Adults With Chronic Kidney Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI